Pharmaceutical The respiratory syncytial virus (RSV) prophylaxis market across the eight major markets (8MM; USA, France, Germany, Italy. Spain, the UK and Australia) is forecast to grow at a compound annual growth rate (CAGR) of 26.7% from $582 million in 2020 to $6.2 billion in 2030, with the pediatric and adult segments accounting for $2.2 billion and $4.0 billion, respectively, according to pharma analytics company GlobalData. 10 December 2024